COVID-19 infection during pregnancy: a systematic review to summarize possible symptoms, treatments, and pregnancy outcomes

Introduction

The world is now facing a new coronavirus disease 2019 (COVID-19, started in December 2019 in Wuhan, China), a major epidemic threat that the world has ever faced [1]. Since then, the virus has spread to 205 countries or territories and infected around 1.2 million people, and around 65 thousand of them died as of April 5, 2020 [2]. These rates of infections and deaths have been changing daily because of their higher transmission capacity. Consequently, the witness countries’ healthcare systems are now facing problems to treat the infected people properly, although many of them are critically infected and need comprehensive care (5%) [3, 4]. Essentially, these increasing rates are reported when the World Health Organization (WHO) has declared COVID-19 as a global pandemic and asked countries to take aggressive measures that are even reflected in countries’ various initiatives [5, 6]. The roots of transmission of this virus from an infected to non-infected person are in contact with an infected person’s respiratory droplets (coughs or sneezes) [7], and touching surfaces or objects that were touched by the infected person [7, 8], and has the capacity to infect 2.28 persons per day [9].

The virus is prevalent in all age clusters, irrespective of sex. However, it could cause more adverse consequences, including deaths for persons who have pre-existing non-communicable diseases, including diabetes, hypertension, chronic respiratory diseases, and cancer [1]. Notably, the majority of deaths reported worldwide have occurred among people who had a history of one or more morbidities, which are often common among the elderly [1, 10]. The causes of death are many, but poor immunity capacity of people with one or more morbidities might be the main.

Women during pregnancy often face several pregnancy-related complications and more susceptible to respiratory pathogens that may put them at a higher risk of adverse consequences. Getting COVID-19 infected at this stage, therefore, may put them in further risk of occurring adverse pregnancy and newborn outcomes, including deaths; however, the estimate is lacking [11]. Similar to the current COVID-19, severe acute respiratory syndrome (SARS) was reported in 2007 and showed devastating consequences if it occurred during pregnancy [9, 12]. Earlier diagnosis of COVID-19 infection status, a clear understanding of all possible symptoms of infection during pregnancy, and proper treatment are important to combat the adverse consequences.

The available studies on the symptoms of COVID-19 were mainly conducted in the general infected people, and fever, cough, fatigue, and shortness of breath were the common symptoms among them [13-18]. These symptoms reported in a few relevant studies vary for pregnant women, which are inconsistent across studies. For instance, Liu et al. [19] identified cough, shortening of breath, and fatigue alongside fever as the most important symptoms of COVID-19 among pregnant women, whereas cough and fever were reported as vital symptoms of COVID-19 in the Zhu et al. [20] study. The treatments provided to the COVID-19 infected pregnant women were also varied. Oxygen support, antiviral therapy, and antibiotic therapy were the treatments provided to the infected pregnant women mentioned in Liu et al. [21] study. Alternatively, Zhu et al.’s study [20] reported that antibiotic therapy was avoided for all infected pregnant women, but oxygen support and antiviral therapy were provided. Under these circumstances, summarizing all possible symptoms and treatments are necessary to assist healthcare personnel. They, thus, would able to make evidence-based decisions to identify infected pregnant women early and provide the most effective treatments. Moreover, knowledge of the possible adverse outcomes would help healthcare personnel to take precautionary measures earlier. Therefore, this study summarized the symptoms, treatments, and pregnancy outcomes of women who were infected with COVID-19 during their pregnancy.

Methods

A systematic review following the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) consensus statement was conducted [22]. Relevant and available studies related to COVID-19 infection among pregnant women were included.

Results

Symptoms of COVID-19 among pregnant women

Table 2 presents the symptoms reported in the included studies. Where available, the symptoms were reported on case-basis included in the studies. Fever (66.7%) and cough (39.4%) were the major symptoms following COVID-19 infection among pregnant women (Figure 2). The other symptoms reported were fatigue (15.2%), breathing difficulties (14.1%), and myalgia (7.1%). Sore throat (5.1%), diarrhea (4%), poor appetite (3%), headache (3%), and malaise (2%) were also reported among pregnant women following COVID-19 infection. Two different pregnant women also reported mulligrubs and cholecystitis, respectively, which were added to the common symptoms.

View this table:

• View inline
• View popup

Table 2.

Detailed case specific symptoms of the COVID-19 infection among pregnant women.

• Download figure
• Open in new tab

Figure 1. Schematic representation of studies included in the systematic review using PRISMA checklist and flow diagram

• Download figure
• Open in new tab

Figure 2. Symptoms of the COVID-19 infection during pregnancy.

Discussion

The world is now experiencing an exponential increase in the COVID-19 infected people, and a significant proportion of them are pregnant women. We summarized the symptoms following COVID-19 infection among pregnant women, and the treatments are commonly provided to them and the outcomes of the pregnancy. A total of nine studies were included in this review, in which 101 infected pregnant women data were analyzed, and the majority of them were in the third trimester of pregnancy. All included studies were conducted in China. Symptoms reported by pregnant women following COVID-19 infection were slightly different from the common symptoms in general infected people, but fever and cough were common. Oxygen and antibiotic therapy were given as treatments for most infected pregnant women. Of the sample analyzed in the eight studies included, 56 of them gave babies following the infection occurred. Approximately 84% of the infected pregnant women had gone through the C-section; around 30% of women had given premature birth, and a total of 18% of these babies were born with LBW. These summary findings will assist healthcare personnel for the better management of pregnant women who have been infected with COVID-19, which potentially reduces adverse consequences for women as well as their babies.

Several questions have been provoked regarding maternal and neonatal safety if women were infected with COVID-19 during pregnancy. The causes are complications following getting infected and evidence of higher adverse consequences if it has happened with existing morbidity, and these could be added to the usual pregnancy and delivery-related complications. These factors may increase the occurrence of adverse maternal health and birth outcomes, although estimates are lacking. Notably, earlier detection of the infection through tests, symptoms, and effective treatments could reduce these risks. As revealed in this study, based on available published research, fever, cough, fatigue, and breathing difficulties are common symptoms among both pregnant women and infected general people following COVID-19 infection [23, 24]. Although most of the symptoms were almost similar, infected pregnant women had some additional symptoms such as sore throat, myalgia, and poor appetite. Postpartum fever was also highly observed in women following delivery. Therefore, close monitoring of these symptoms could be an effective way of early detection of COVID-19 infection during pregnancy. Previous corona-like virus outbreaks, such as infection of SARS during pregnancy, reported malaise, chills, and rigors as common symptoms along with fever, cough, and breathing difficulties [25].

Given that no specific treatments or vaccines have been discovered yet, the COVID-19 infection during pregnancy would put healthcare providers in additional challenges [23]. This is because of the possible adverse effects of the medicine used on the fetus as well as pregnancy. For instance, there is evidence that medicines such as chloroquine and hydroxychloroquine are currently recommended for patients with COVID-19 [26], which may cause fetal harm [27] and adversely affect newborns through transferring from mother body by breastmilk [28, 29]. Therefore, cautions are needed in the treatment of infected pregnant women. This study revealed that most infected pregnant women were given symptomatic and supportive treatments considering pregnancy, although anti-inflammatory and antiviral treatments have been used in some cases [30, 31]. Significantly, this study summarized the commonly given antiviral treatments to the infected pregnant women were oseltamivir, lopinavir (400mg), and ritonavir (100mg), which are different from usually recommended medicines to treat COVID-19 in the general population [26]. Therefore, healthcare providers may have to be careful about given antiviral treatments to infected pregnant women.

Additionally, oxygen therapy and antibiotic therapy (e.g., cefoperazone sodium) have been used in some cases [31, 32]. Notably, further cautious measures are needed to choose the medicine from previous experience with SARS and its treatments, which is considered like COVID-19 infection, and there are many similarities in treatments given for these infections. For instance, oxygen and antiviral therapy (drugs, including ribavirin, ritonavir, and lopinavir) are used in both SARS and COVID-19 [33]. However, corticosteroids were not used to treat COVID-19, although it was used to treat SARS among pregnant women. There is evidence that the use of corticosteroids during pregnancy increases the risk of preterm birth, low birth weight, and preeclampsia [34].

Additional important findings of this study were the higher occurrence of adverse maternal newborn outcomes among COVID-19 infected mothers. For example, as this study reported, around 84% of the infected mothers had birth reported use of the C-section; a rate that is significantly higher than the usual WHO’s recommendation of 1-5% use of C-section to avoid death and severe morbidity in mothers and newborns [35, 36]. Getting COVID-19 infection increases complex viral infection among women in pregnancy; therefore, C-section is recommended to reduce perinatal and neonatal adverse outcomes [37]. We also confirm the evidence of the higher occurrence of preterm birth and LBW among the COVID-19 infected mothers than their counterparts. These associations are unique, as the previous round of viral infection, such as SARS, did not find any evidence of the association between infection during pregnancy and occurrence of LBW and preterm birth [38-41]. Viral infection affects pregnancy and fetal growth by gaining access to the placenta and decidua via hematogenous transmission or the lower reproductive tract, leading to the occurrence of such adverse outcomes [42]. However, effects can vary across cell types, gestational age, and changes in the uterine environment and maternal immunity [42]. Therefore, earlier preparedness of the healthcare sectors to handle these adverse consequences would be helpful to reduce further adverse outcomes, including maternal and perinatal mortality.

This study has several strengths and limitations. This is the first study of its kind that highlight the symptoms, treatments, and pregnancy outcomes among women who have been infected with COVID-19. These findings may help healthcare providers to take proper initiatives. We did not set any time and study design restrictions that allowed us to include a higher number of studies. However, the major limitation is generalizability because all included studies were conducted in China. Different treatments may be used to treat COVID-19 during pregnancy in other countries. Moreover, none of the included studies reported quantitative data that restrict us to conduct a narrative synthesis of the selected study’s findings rather than given any pool estimates. Despite these limitations, this study has enough merits, which will make healthcare providers informed about the symptoms, treatments, and possible outcomes in pregnant women detected with COVID-19.

Conclusion

This study confirms that fever, cough, and breathing difficulties are the major symptoms of COVID-19 infection among pregnant women, which are similar to general infected patients. However, some additional symptoms among pregnant women are postpartum fever and breathing difficulties. Recommended treatments such as chloroquine and hydroxychloroquine for the infected people are not applicable for pregnant women because of their potential adverse effects on the fetus and newborn; therefore, supportive and symptomatic treatments are given to them. COVID-19 infection during pregnancy also increases the risk of several adverse outcomes, including higher rates of cesarean delivery, low birth weight, and preterm birth. Healthcare providers may consider these for effective management of COVID-19 infected pregnant women, which would reduce pregnancy-related adverse consequences, including maternal and newborn morbidity and mortality.

Authors Contribution

Conceptualization: MMAK

Research design: MMAK and MNK

Data curation: MMAK and MGM

Analysis: MMAK, MGM, and MNK

Draft preparation: MMAK, MNK, MGM, JR, MMR, and MRH

Supervision: MNK

Critical review and edits: JR, MNK, MMR, and MRH

Conflicts of interest

The authors have no competing interests to declare.

Funding

The authors received no funds for this study.